drugset / Trial / NCT02271958

Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis

NCT02271958

Phase 2/3 Completed 360 enrolled Mediterranea Medica S. L.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of 2.5, 5 and 10 mg doses of mifepristone against a placebo in women with laparoscopic diagnostic of endometriosis. The hypothesis of the study is that the 5 mg mifepristone dose is safe and effective and should be used in future studies on medical treatment of endometriosis.

Timeline

Start
2010-11
Primary completion
2013-10
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 2.5 mg Oral
Subject Mifepristone Small molecule 5 mg Oral
Subject Mifepristone Small molecule 10 mg Oral

Indications